ストックスクリーナーアプリを入手
3.1362
1.13%
0.0362
前日終値:
$3.10
開ける：
$3.1
24時間の取引高:
166.76K
Relative Volume:
0.16
時価総額：
$237.61M
収益：
-
当期純損益:
$-45.62M
株価収益率:
-5.2762
EPS:
-0.5944
ネットキャッシュフロー:
$-62.34M
1週間 パフォーマンス:
+2.12%
1か月 パフォーマンス:
+8.10%
6か月 パフォーマンス:
+14.42%
1年 パフォーマンス:
+10.78%
1日の値動き範囲:
$3.09
$3.18
1週間の範囲:
$2.97
$3.28
52週間の値動き範囲:
$1.35
$4.60
Eledon Pharmaceuticals Inc Stock (ELDN) Company Profile
名前
Eledon Pharmaceuticals Inc
セクター
電話
949-238-8090
住所
19800 MACARTHUR BLVD., IRVINE
Compare ELDN vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ELDN
Eledon Pharmaceuticals Inc
|
3.1326 | 237.42M | 0 | -45.62M | -62.34M | -0.5944 |
VRTX
Vertex Pharmaceuticals Inc
|
443.95 | 112.92B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
760.46 | 81.99B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
804.43 | 48.82B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
326.49 | 43.66B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.53 | 34.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Eledon Pharmaceuticals Inc Stock (ELDN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-06-18 | 再開されました | H.C. Wainwright | Buy |
| 2025-01-28 | 開始されました | Guggenheim | Buy |
| 2022-05-13 | 再開されました | Cantor Fitzgerald | Overweight |
| 2021-03-23 | 開始されました | Cantor Fitzgerald | Overweight |
Eledon Pharmaceuticals Inc (ELDN) 最新ニュース
Can Eledon Pharmaceuticals Inc expand its profit marginsMarket Movement Recap & Safe Capital Growth Plans - baoquankhu1.vn
Market Review: Can Eledon Pharmaceuticals Inc outperform under higher oil pricesRecession Risk & Reliable Intraday Trade Alerts - baoquankhu1.vn
Gainers Report: What hedge funds are buying Eledon Pharmaceuticals Inc2026 Trade Ideas & Safe Capital Growth Stock Tips - baoquankhu1.vn
After islet transplants, 10 diabetes patients stopped using insulin - Stock Titan
Insider Sell: Can Eledon Pharmaceuticals Inc outperform under higher oil pricesWeekly Stock Report & Technical Buy Zone Confirmations - baoquankhu1.vn
Why Smart Money Is Shifting From Clinical Data to Manufacturing Lines - Sahm
Eledon Pharmaceuticals Inc (2TK.SG) - Yahoo! Finance Canada
ELDN Forecast, Price Target & Analyst Ratings | ELEDON PHARMACEUTICALS INC (NASDAQ:ELDN) - ChartMill
Short Interest in Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Rises By 30.3% - marketbeat.com
Eledon Pharmaceuticals (ELDN) Price Target Decreased by 14.93% to 8.33 - MSN
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Geopolitics Watch: What hedge funds are buying Eledon Pharmaceuticals Inc2026 News Drivers & Stepwise Trade Execution Plans - baoquankhu1.vn
Vanguard disaggregates holdings after realignment; Eledon (ELDN) showing 0 shares - Stock Titan
What is Noble Financial's Forecast for ELDN Q1 Earnings? - MarketBeat
Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Deliver On Growth Plans? - Sahm
Midday Stock Roundup: RxSight Climbs 7% - Orange County Business Journal
Eledon Unveils New Type 1 Diabetes Data - Orange County Business Journal
Noble Financial Maintains Eledon Pharmaceuticals(ELDN.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Eledon Pharmaceuticals, Inc.: Fundamental Analysis and Financial Ratings | 2TK | US28617K1016 - marketscreener.com
If You Invested $1,000 in Eledon Pharmaceuticals Inc (ELDN) - Stock Titan
Eledon Pharmaceuticals, Inc. 2026 Annual Report: Business Overview, Risk Factors, and Strategic Focus on Immunology and Tegoprubart Development 29 - Minichart
Eledon Pharmaceuticals Reports Positive 2025 Results for Tegoprubart in Transplant Trials and Receives FDA Orphan Drug Designation - Minichart
Eledon Pharmaceuticals (NASDAQ:ELDN) Announces Quarterly Earnings Results, Beats Expectations By $0.10 EPS - MarketBeat
ELEDON PHARMACEUTICALS ($ELDN) Releases Q4 2025 Earnings, Stock Rises - Quiver Quantitative
Eledon Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Operating and Financial Results - The Manila Times
Eledon Pharmaceuticals 2025 net loss widens on higher R&D costs - TradingView
Eledon (NASDAQ: ELDN) 2025 results show higher R&D spend and cash - Stock Titan
Tegoprubart data and new orphan status headline Eledon (NASDAQ: ELDN) 2025 update - Stock Titan
Eledon Pharmaceuticals options imply 11.7% move in share price post-earnings - TipRanks
After islet transplants, 10 Eledon-treated diabetes patients went off insulin - Stock Titan
ELDN PE Ratio & Valuation, Is ELDN Overvalued - Intellectia AI
Eledon reports insulin independence in islet transplant trial By Investing.com - Investing.com Australia
Leerink Maintains Outperform on ELDN (Eledon Pharmaceuticals) March 16, 2026 - Meyka
Eledon Pharmaceuticals (ELDN) Presents Promising Diabetes Trial Results - GuruFocus
Eledon Pharmaceuticals (ELDN) Reports Promising Results for Tego - GuruFocus
Eledon Pharmaceuticals: Tegoprubart Continues To Shine As Immunosuppressive Alternative - Seeking Alpha
Eledon’s Transplant Drug Is Heading Toward A Phase 3 Moment - Finimize
Leerink Partners reiterates Outperform on Eledon stock at $5 By Investing.com - Investing.com Canada
Eledon announces updated data from investigator-initiated islet transplant trial of tegoprubart in patients with type 1 diabetes at UChicago Medicine - marketscreener.com
Eledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at UChicago Medicine - Bitget
Eledon reports insulin independence in islet transplant trial - Investing.com
Eledon Pharmaceuticals Inc expected to post a loss of 20 cents a shareEarnings Preview - TradingView
Experimental transplant drug lets 10 diabetes patients stop insulin - Stock Titan
Eledon Pharmaceuticals Touts Tegoprubart Safety in BESTOW Kidney Transplant Data at Leerink Conference - MarketBeat
symbol__ Stock Quote Price and Forecast - CNN
Eledon Pharmaceuticals (ELDN) to Release Quarterly Earnings on Thursday - MarketBeat
Eledon Pharmaceuticals at Leerink Conference: Strategic Insights on Transplantation By Investing.com - Investing.com Canada
ELDN: Tegoprubart advances with strong safety data, phase 3 plans, and cash runway into Q2 2025 - TradingView
NewcelX partners with Eledon on type 1 diabetes therapy By Investing.com - Investing.com Nigeria
Eledon Pharmaceuticals Announces Orphan Drug Designation - GlobeNewswire
Eledon Pharmaceuticals Inc (ELDN) 財務データ
収益
当期純利益
現金流量
EPS
1.27%
0.41%
大文字化:
|
ボリューム (24 時間):